July 27, 2020 -- Cerevel Therapeutics and Cyclica have announced a research collaboration that will use artificial intelligence (AI) to develop new neurological medicines.
The companies will develop an AI-augmented, integrated technology platform, that will enable multiobjective, polypharmacology-informed drug design. Cerevel will use Cyclica's Ligand Express and Ligand Design AI platforms to identify potential leads for new medicines, the two firms said.
The platform will be used to screen, identify, design, and evaluate compounds. Cerevel has at least five clinical and seven preclinical pipelines for several neurological indications under development utilizing the platform. Cyclica's AI platform will help accelerate drug discovery and in silico drug design of Cerevel's targets.